Enveric Biosciences, Inc.
For the period ended Mar 27, 2026. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 27, 2026 · Filed Mar 27, 2026
Use the contents to explore the available documents and sections.
ENVB$1.42+1.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · EB-003 Development:
EB-003 Development:
| ● | Received FDA response allowing for streamlined plans for EB-003 IND submission |
| ● | Successfully completed pre-IND dose range finding studies for EB-003 establishing maximum tolerated dose, supporting progression of EB-003 toward IND-enabling studies and first-in-human clinical trials |
| ● | Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in a preclinical model of severe chronic depression and despair |
| ● | Announced positive results in treatment in preclinical, exposure-based therapeutic model for post-traumatic stress disorder (PTSD) showing significantly decreased context-induced freezing behavior one-hour post-dose of EB-003 |
| ● | Achieved key manufacturing milestones in the chemistry, manufacturing, and controls (CMC) development of EB-003, key steps in scaling production and preparing the drug for required regulatory activities |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.